{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:57:58Z","timestamp":1788541078564,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008893","name":"University of Iowa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008893","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.soc.2019.11.006","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T18:37:58Z","timestamp":1583519878000},"page":"223-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Management of Small Bowel Neuroendocrine Tumors"],"prefix":"10.1016","volume":"29","author":[{"given":"Aaron T.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2019.11.006_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF02114017","article-title":"Ueber einen Dr\u00fcsenpolyp im ileum","volume":"38","author":"Langhans","year":"1867","journal-title":"Virchows Arch"},{"key":"10.1016\/j.soc.2019.11.006_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF01966242","article-title":"Ueber den prim\u00e4ren Krebs des Ileum nebst Bemerkungen \u00fcber das gleichzeitige Vorkommen von Krebs und Tuberculose","volume":"111","author":"Lubarsch","year":"1888","journal-title":"Virchows Arch"},{"issue":"3507","key":"10.1016\/j.soc.2019.11.006_bib3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0140-6736(00)64173-9","article-title":"A\u00a0case of primary carcinoma of the ileum","volume":"136","author":"Ransom","year":"1890","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2019.11.006_bib4","first-page":"425","article-title":"Karzinoide Tumoren des D\u00fcnndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2019.11.006_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1530\/ERC-11-0013","article-title":"Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms","volume":"18","author":"Kloppel","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"7275","key":"10.1016\/j.soc.2019.11.006_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.soc.2019.11.006_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib8","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"issue":"18","key":"10.1016\/j.soc.2019.11.006_bib11","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"10.1016\/j.soc.2019.11.006_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00268-010-0519-z","article-title":"Epidemiology of small bowel carcinoids in a defined population","volume":"34","author":"Landerholm","year":"2010","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1245\/s10434-011-1997-4","article-title":"Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution","volume":"19","author":"Dahdaleh","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-12-0340","article-title":"Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database","volume":"20","author":"Ter-Minassian","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","article-title":"Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center","volume":"36","author":"Norlen","year":"2012","journal-title":"World J Surg"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","article-title":"Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical presentation and diagnosis of neuroendocrine tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.soc.2019.11.006_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctrv.2016.05.003","article-title":"Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus","volume":"47","author":"Singh","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.soc.2019.11.006_bib21","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","article-title":"Carcinoid tumors and fibrosis: an association with no explanation","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.soc.2019.11.006_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.dld.2011.04.021","article-title":"Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study","volume":"43","author":"Le Roux","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.soc.2019.11.006_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/RLU.0000000000000533","article-title":"A\u00a0frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET\/CT uptake by primary site-dependent neuroendocrine tumor metastasis","volume":"39","author":"Kunikowska","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1016\/j.soc.2019.11.006_bib24","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihimaki","year":"2016","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.soc.2019.11.006_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.beem.2015.09.005","article-title":"Carcinoid heart disease: diagnosis and management","volume":"30","author":"Luis","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MPA.0b013e3181bc0e77","article-title":"Biochemical testing for neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib30","doi-asserted-by":"crossref","first-page":"e0124884","DOI":"10.1371\/journal.pone.0124884","article-title":"Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.soc.2019.11.006_bib31","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","article-title":"Pancreastatin predicts survival in neuroendocrine tumors","volume":"21","author":"Sherman","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MPA.0000000000001263","article-title":"Plasma pancreastatin predicts the outcome of surgical cytoreduction in neuroendocrine tumors of the small bowel","volume":"48","author":"Woltering","year":"2019","journal-title":"Pancreas"},{"issue":"12","key":"10.1016\/j.soc.2019.11.006_bib33","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1245\/s10434-018-6741-x","article-title":"Prognostic impact of serum pancreastatin following chemoembolization for neuroendocrine tumors","volume":"25","author":"Strosberg","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/ije.14.40","article-title":"Imaging in neuroendocrine tumors: an update for the clinician","volume":"2","author":"Maxwell","year":"2015","journal-title":"Int J Endocr Oncol"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.surg.2016.05.055","article-title":"Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors","volume":"161","author":"Keck","year":"2017","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2019.11.006_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2967\/jnumed.110.083741","article-title":"68Ga-DOTATOC PET\/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol","volume":"52","author":"Ruf","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.soc.2019.11.006_bib41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00261-018-1496-1","article-title":"Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent","volume":"43","author":"Tirumani","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2019.11.006_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000080742","article-title":"Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment","volume":"80","author":"Reubi","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00330-015-3882-1","article-title":"Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET\/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours","volume":"26","author":"Van Binnebeek","year":"2016","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.soc.2019.11.006_bib45","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.soc.2019.11.006_bib46","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1245\/s10434-015-4471-x","article-title":"Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach","volume":"22","author":"Squires","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2019.11.006_bib47","article-title":"Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET\/CT in the management of GEP-NENs: a systematic review","volume":"8","author":"Carideo","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.soc.2019.11.006_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAP.0b013e3182a2dc67","article-title":"Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry","volume":"20","author":"Bellizzi","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.soc.2019.11.006_bib49","year":"2019"},{"issue":"12","key":"10.1016\/j.soc.2019.11.006_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A\u00a0common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib51","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1245\/s10434-017-5899-y","article-title":"Increased grade in neuroendocrine tumor metastases negatively impacts survival","volume":"24","author":"Keck","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2019.11.006_bib52","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"issue":"11","key":"10.1016\/j.soc.2019.11.006_bib53","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1245\/s10434-018-6676-2","article-title":"The distal predilection of small bowel neuroendocrine tumors","volume":"25","author":"Keck","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2019.11.006_bib54","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00268-013-1918-8","article-title":"Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors","volume":"37","author":"Landry","year":"2013","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamasurg.2018.3865","article-title":"Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors","volume":"154","author":"Zaidi","year":"2019","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.soc.2019.11.006_bib56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s002680010232","article-title":"Method for dissection of mesenteric metastases in mid-gut carcinoid tumors","volume":"24","author":"Ohrvall","year":"2000","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000365143","article-title":"Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections","volume":"90","author":"Dieckhoff","year":"2014","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000225952","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation","volume":"90","author":"Arnold","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","article-title":"Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)","volume":"165","author":"Scott","year":"2019","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib60","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","article-title":"Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients","volume":"156","author":"Graff-Baker","year":"2014","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.soc.2019.11.006_bib61","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J\u00a0Am Coll Surg"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib63","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.surg.2008.06.008","article-title":"The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors","volume":"144","author":"Chambers","year":"2008","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jamcollsurg.2013.12.035","article-title":"A\u00a0single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors","volume":"218","author":"Boudreaux","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib66","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/00365521.2019.1647281","article-title":"Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection","volume":"54","author":"Fossmark","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","article-title":"Long-term survival after surgical management of neuroendocrine hepatic metastases","volume":"12","author":"Glazer","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0011-3840(81)80009-3","article-title":"Liver metastases","volume":"18","author":"Foster","year":"1981","journal-title":"Curr Probl Surg"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib69","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","article-title":"Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?","volume":"47","author":"Mazzaferro","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib72","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00268-013-2331-z","article-title":"Indication for liver transplantation in young patients with small intestinal NETs is rare?","volume":"38","author":"Norlen","year":"2014","journal-title":"World J Surg"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib73","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1686::AID-CNCR8>3.0.CO;2-C","article-title":"Peritoneal carcinomatosis in patients with digestive endocrine tumors","volume":"78","author":"Vasseur","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib74","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.surg.2014.08.090","article-title":"Peritoneal carcinomatosis from small intestinal neuroendocrine tumors: clinical course and genetic profiling","volume":"156","author":"Norlen","year":"2014","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib75","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","article-title":"Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)","volume":"155","author":"Elias","year":"2014","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib76","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2019.11.006_bib77","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/SLA.0000000000002809","article-title":"Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment","volume":"270","author":"Lewis","year":"2019","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.soc.2019.11.006_bib78","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ejso.2017.05.016","article-title":"Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: a systematic review and meta-analysis","volume":"43","author":"Almond","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2019.11.006_bib79","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s11605-018-04094-9","article-title":"Is resection of primary midgut neuroendocrine tumors in patients with unresectable metastatic liver disease justified? A systematic review and meta-analysis","volume":"23","author":"Tsilimigras","year":"2019","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.soc.2019.11.006_bib80","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.amjsurg.2011.12.010","article-title":"Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors","volume":"203","author":"Massimino","year":"2012","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#","article-title":"Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors","volume":"79","author":"Trendle","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/bja\/87.3.447","article-title":"Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours","volume":"87","author":"Kinney","year":"2001","journal-title":"Br J Anaesth"},{"issue":"8","key":"10.1016\/j.soc.2019.11.006_bib83","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2015.09.010","article-title":"Hepatic-directed therapies in patients with neuroendocrine tumors","volume":"30","author":"Kennedy","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.soc.2019.11.006_bib85","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jvir.2014.12.009","article-title":"Radiofrequency ablation for neuroendocrine liver metastases: a systematic review","volume":"26","author":"Mohan","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.soc.2019.11.006_bib86","doi-asserted-by":"crossref","first-page":"973946","DOI":"10.1155\/2012\/973946","article-title":"Treatment of neuroendocrine tumor liver metastases","volume":"2012","author":"Lewis","year":"2012","journal-title":"Int J Hepatol"},{"issue":"28","key":"10.1016\/j.soc.2019.11.006_bib87","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib88","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9808","key":"10.1016\/j.soc.2019.11.006_bib89","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"10022","key":"10.1016\/j.soc.2019.11.006_bib90","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MPA.0000000000001005","article-title":"Long-term outcomes of gastroenteropancreatic neuroendocrine tumors","volume":"47","author":"Chi","year":"2018","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.soc.2019.11.006_bib95","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000494293","article-title":"Health-related quality of life in patients with small intestine neuroendocrine tumors","volume":"107","author":"Karppinen","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.soc.2019.11.006_bib96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/diagnostics5020119","article-title":"Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review","volume":"5","author":"Ilett","year":"2015","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.soc.2019.11.006_bib97","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.11.006_bib98","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000473892","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy","volume":"105","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719301024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719301024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:03:03Z","timestamp":1760961783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320719301024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1055320719301024"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2019.11.006","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Small Bowel Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2019.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}